MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer

被引：1
|
作者：
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-GS01-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS01-12
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Price, Gregory L.
    Lin, Yong
    Boye, Mark
    Li, Li
    Gable, Jonathon
    Carter, Gebra Cuyun
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [43] Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trial
    Xu, B.
    Zhang, Q. Y.
    Zhang, P.
    Tong, Z.
    Sun, T.
    Li, W.
    Ouyang, Q.
    Hu, X.
    Cheng, Y.
    Yan, M.
    Teng, Y.
    Pan, Y.
    Yan, X.
    Wang, Y.
    Xie, W.
    Zeng, X.
    Jiang, S.
    Bayaxi, N.
    Zhu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1385
  • [44] Time trends in overall survival and systemic therapy in patients with HR+/HER2-advanced breast cancer: A study of the SONABRE registry
    Meegdes, M.
    Geurts, S. M. E.
    Erdkamp, F. L. G.
    Dercksen, W.
    Vriens, B. E. P. J.
    Aaldering, K. N. A.
    Pepels, M. J. A. E.
    Winkel, L. V. D.
    Tol, J.
    Heijns, J. B.
    van de Wouw, A. J.
    Peters, N.
    Fallois, A. J. O.
    van Kats, M. A. C. E.
    Tjan-Heijnen, V. C. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S209 - S209
  • [45] Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [46] Overall survival in Japanese patients with ER+/HER2-advanced breast cancer treated with first-line palbociclib plus letrozole
    Takahashi, Masato
    Osako, Tomofumi
    Yasojima, Hiroyuki
    Inoue, Kenichi
    Kawashima, Masahiro
    Maeda, Hideki
    Ichikawa, Akemi
    Muramatsu, Yasuaki
    Masuda, Norikazu
    BREAST CANCER, 2024, 31 (01) : 53 - 62
  • [47] Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)
    Takahashi, Masato
    Osako, Tomofumi
    Yasojima, Hiroyuki
    Inoue, Kenichi
    Kawashima, Masahiro
    Maeda, Hideki
    Ito, Mitsuya
    Sagara, Yasuaki
    Yonemori, Kan
    Hattori, Masaya
    Yamamoto, Naohito
    Tokunaga, Eriko
    Ohsumi, Shozo
    Yamamoto, Yutaka
    Ichikawa, Akemi
    Muramatsu, Yasuaki
    Masuda, Norikazu
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
    Rugo, Hope S.
    Brufsky, Adam
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Layman, Rachel M.
    Cristofanilli, Massimo
    Torres, Mylin A.
    Curigliano, Giuseppe
    Finn, Richard S.
    DeMichele, Angela
    NPJ BREAST CANCER, 2022, 8 (01)
  • [49] Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials
    Rugo, H. S.
    Tolaney, S. M.
    Huober, J.
    Toi, M.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, G. W.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
    Hope S. Rugo
    Adam Brufsky
    Xianchen Liu
    Benjamin Li
    Lynn McRoy
    Connie Chen
    Rachel M. Layman
    Massimo Cristofanilli
    Mylin A. Torres
    Giuseppe Curigliano
    Richard S. Finn
    Angela DeMichele
    npj Breast Cancer, 8
12345